SALEM, Mass., Aug. 21 /PRNewswire/ -- LaVoie Strategic Communications Group, Inc. (LaVoie Group), a life sciences focused public and investor relations firm, announced today that it has been selected by privately-held Transport Pharmaceuticals, Inc. of Framingham, MA as agency of record.
"LaVoie Group is focused on providing senior level strategic counsel and superior tactical execution to our growing roster of global life science clients. Transport Pharmaceuticals is a drug/device company focused in dermal diseases with core competencies in engineering, chemistry, and biology and drug development. We look forward to working and growing with Transport's management team as they progress into their next phase of clinical development," said Donna L. LaVoie, President and CEO, LaVoie Group.
About LaVoie Group
LaVoie Group provides senior level strategic counsel and tactical implementation of public, investor and corporate communications programs designed to properly position and create visibility that drives value for our clients. Our public and private clients range from start-ups to industry leaders, in multiple international markets.
About Transport Pharmaceuticals, Inc.
Transport Pharmaceuticals, Inc., is a privately-held company developing and designing drug/device combination products for the treatment of multiple dermatological diseases. The Company's lead product, SoloVir(TM), utilizes a proprietary drug formulation and an electrokinetic delivery-device to create a revolutionary paradigm shift in patient initiated treatment of herpes labialis, or cold sores.
Donna L. LaVoie
President & CEO
LaVoie Strategic Communications Group, Inc.
CONTACT: Donna L. LaVoie, President & CEO of LaVoie Group,+1-978-745-4200, ext. 103, email@example.com